Soluble thrombomodulin and coronary heart disease

Current Opinion in Lipidology

Volumn 14, Issue 4, 2003, Pages 373-375

  Wu, Kenneth K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Coronary heart disease; Risk assessment; Soluble intercellular adhesion molecule 1; Soluble thrombomodulin

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; THROMBOMODULIN;

ADULT; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; COHORT STUDIES; CORONARY DISEASE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOMODULIN;

EID: 0043127016     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200308000-00006     Document Type: Review

References (15)

1. Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997; 78;392-395.
2. Esmon CT, Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9:946-955.
3. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A 1995; 92:850-854.
4. Weiler-Guettler H, Christie PD, Beeler DL, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998; 101:1983-1991.
5. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76:2178-2181.
6. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65:618-623.
7. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129:687-702.
8. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 1996; 49:223-233.
9. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study, 1987 to 1994. N Engl J Med 1998; 339:861-867.
10. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96:1102-1108.
11. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in ARIC study: a case-cohort study. Lancet 1999; 353:1729-1734.
12. Albelda SM, Smith CW, Ward PA. Adhesive molecules and inflammatory injury. FASEB J 1994; 8:504-512.
13. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated endothelial cells. Biochem Biophys Res Commun 1989; 187:584-589.
14. Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997; 96:4219-4225.
15. Wu KK, Aleksic N, Ballantyne CM, et al. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation 2003; 107:1729-1732.